Daiichi gets speedy FDA review for rare cancer drug

Daiichi gets speedy FDA review for rare cancer drug

Source: 
Pharmaforum
snippet: 

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT).